Innbiogem

InnBioGem is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of mRNA-based vaccines and therapeutics. Founded in 2020 by Dr. Wang Bing, a former executive at Moderna, the company leverages proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery technologies to address infectious diseases and oncology. Its lead program, IBG-001, is an mRNA vaccine candidate for COVID-19 that has progressed into Phase 2 clinical trials. Beyond infectious diseases, InnBioGem is advancing a pipeline of personalized cancer vaccines and protein replacement therapies for rare diseases. The company is backed by prominent venture capital firms, including Hillhouse Capital and Sherpa Healthcare Partners, and aims to provide innovative mRNA solutions for global health challenges.